Plaquverazon indications
This combination medication is used to treat certain skin conditions such as psoriasis. It combines a chemical related to vitamin D (Calcipotriol (Plaquverazon)) with a corticosteroid (Betamethasone (Plaquverazon)) that reduces swelling/inflammation and itching. This product is not recommended for use in children.
Plaquverazon description
Each gram of ointment contains Calcipotriol (Plaquverazon) 50 mcg and Betamethasone (Plaquverazon) dipropionate 0.5 mg.
Each gram of Plaquverazon gel contains Calcipotriol (Plaquverazon) monohydrate 50 mcg and Betamethasone (Plaquverazon) dipropionate 0.5 mg. It also contains the following excipients: Liquid paraffin, butylhydroxytoluene (E321), polyoxypropylene-15 stearyl ether, all-rac-α-tocopherol, hydrogenated castor oil.
Plaquverazon dosage
Gel: Plaquverazon should be applied to the affected area once daily. The recommended treatment duration is 4 weeks. After this period, repeated treatment with Plaquverazon can be initiated under medical supervision. The maximum daily dose should not exceed 15 g, the maximum weekly dose should not exceed 100 g and the treated area should not be >30% of the body surface area.
Plaquverazon gel should be applied to affected areas of the scalp once daily. The recommended treatment period is 8 weeks for non-scalp areas. After this period repeated treatment with Plaquverazon gel can be initiated under medical supervision.
All the affected scalp areas may be treated with Plaquverazon gel. Usually an amount between 1 g and 4 g daily is sufficient for treatment of the scalp (4 g corresponds to 1 teaspoon).
When using Calcipotriol (Plaquverazon) containing products, the maximum daily dose should not exceed 15 g, and the maximum weekly dose should not exceed 100 g. The body surface area (BDA) treated with Calcipotriol (Plaquverazon) containing products should not exceed 30%.
Administration: Gel: Shake the bottle before use. In order to achieve optimal effect, it is recommended that the hair is not washed immediately after application of Plaquverazon gel. Plaquverazon gel should remain on the skin during the night or during the day.
Plaquverazon interactions
No interaction studies have been performed.
Incompatibilities: In the absence of compatibility studies, Plaquverazon gel must not be mixed with other medicinal products.
Plaquverazon side effects
The trial programme for Plaquverazon ointment has so far included >2500 patients for Plaquverazon ointment and >4,700 patients for Plaquverazon Gel and has shown that approximately 10% and 8% of patients can be expected to experience a non-serious undesirable effect for Plaquverazon Gel and Ointment, respectively.
Based on data from clinical trials and post-market use, the common undesirable effects are pruritus, rash and burning sensation of skin. Uncommon undesirable effects are skin pain or irritation, dermatitis, erythema, exacerbation of psoriasis, folliculitis and application site pigmentation changes. Pustular psoriasis is a rare undesirable effect.
The individual undesirable effects are listed as follows, starting with the most frequently reported:
Skin and Subcutaneous Tissue Disorders: Common (>1/100 and <1/10): Pruritus, rash, burning sensation of skin. Uncommon (>1/1000 and <1/100): Skin pain or irritation, dermatitis, erythema, exacerbation of psoriasis, folliculitis, application site pigmentation changes. Rare (>1/10,000 and <1/1000): Pustular psoriasis.
Undesirable effects observed for Calcipotriol (Plaquverazon) and Betamethasone (Plaquverazon), respectively:
Calcipotriol (Plaquverazon): Undesirable effects include application site reactions, pruritus, skin irritation, burning and stinging sensations, dry skin, erythema, rash, dermatitis, eczema, aggravated psoriasis, photosensitivity and hypersensitivity reactions including very rare cases of angioedema and facial oedema. Systemic effects after topical use may appear very rarely causing hypercalcaemia or hypercalciuria.
Betamethasone (Plaquverazon) (as Dipropionate): Plaquverazon contains a potent corticosteroid.
Local reactions can occur after topical use, especially during prolonged application, including skin atrophy, telangiectasia, striae, folliculitis, hypertrichosis, perioral dermatitis, allergic contact dermatitis, depigmentation and colloid milia. When treating psoriasis, there may be a risk of generalised pustular psoriasis.
Systemic effects due to topical use of corticosteroids are rare in adults, however they can be severe. Adrenocortical suppression, cataract, infections and increase of intraocular pressure can occur, especially after long-term treatment. Systemic effects occur more frequently when applied under occlusion (plastic, skin folds), when applied on large areas and during long-term treatment.
Plaquverazon contraindications
Hypersensitivity to Calcipotriol (Plaquverazon) monohydrate or Betamethasone (Plaquverazon) dipropionate gel or to any of the excipients of Plaquverazon.
Due to the content of Calcipotriol (Plaquverazon), Plaquverazon gel is contraindicated in patients with known disorders of calcium metabolism.
Due to the content of corticosteroid, Plaquverazon gel is contraindicated in the following conditions: Viral (eg, herpes or varicella) lesions of the skin, fungal or bacterial skin infections, parasitic infections, skin manifestations in relation to tuberculosis or syphilis, perioral dermatitis, atrophic skin, striae atrophicae, fragility of skin veins, ichthyosis, acne vulgaris, acne rosacea, rosacea, ulcers and wounds.
Plaquverazon gel is contraindicated in guttate, erythrodermic, exfoliative and pustular psoriasis. It is also contraindicated in patients with severe renal insufficiency or severe hepatic disorders.
Active ingredient matches for Plaquverazon:
Betamethasone/Calcipotriol in Egypt.
List of Plaquverazon substitutes (brand and generic names) | Sort by popularity |
| Unit description / dosage (Manufacturer) | Price, USD |
| Calcipotriol/Betamethasone Sandoz 50/500 (Australia) | |
| Cutanit B (Argentina) | |
| Daivobet (Australia, Bahrain, Bangladesh, Bulgaria, China, Colombia, Costa Rica, Czech Republic, Denmark, Dominican Republic, Ecuador, El Salvador, Estonia, Finland, France, Georgia, Germany, Guatemala, Honduras, Hong Kong, Iceland, India, Indonesia, Israel, Latvia, Lithuania, Malaysia, Malta, Norway, Panama, Philippines, Poland, Portugal, Romania, Russian Federation, Singapore, Slovenia, South Korea, Spain, Sweden, Switzerland, Taiwan, Tunisia, Uruguay, Vietnam) | |
| Ointment; Topical; Betamethasone Dipropionate 0.05%; Calcipotriol Hydrate 0.005% (Win Medicare Pvt Ltd) | |
| Daivobet Calcipotriol 50 mcg, Betamethasone 0.5 mg/1 g. OINT / 15g (Win Medicare Pvt Ltd) | $ 9.80 |
| Daivobet 15 g (Win Medicare Pvt Ltd) | $ 22.24 |
| Daivobet 15 g x 1's (Win Medicare Pvt Ltd) | $ 23.93 |
| Daivobet 30 g (Win Medicare Pvt Ltd) | $ 38.37 |
| Daivobet 1 tube 15 g (Win Medicare Pvt Ltd) | |
| 15g (Win Medicare Pvt Ltd) | $ 9.80 |
| Daivobet Skin 15 gm Ointment (Win Medicare Pvt Ltd) | $ 0.62 |
| Daivobet oint 15 g x 1's (Win Medicare Pvt Ltd) | $ 22.91 |
| Daivobet oint 30 g x 1's (Win Medicare Pvt Ltd) | $ 41.18 |
| Daivobet gel 15 g x 1's (Win Medicare Pvt Ltd) | |
| Daivobet gel 30 g x 1's (Win Medicare Pvt Ltd) | $ 41.98 |
| Daivobet gel 60 g x 1's (Win Medicare Pvt Ltd) | |
| DAIVOBET oint 15g (Win Medicare Pvt Ltd) | $ 9.33 |
| Daivobet 50 µg/0.5 mg/g (Hungary) | |
| Daivobet 50 µg/g + 0,5 mg/g (Austria, Germany) | |
| Daivobet 50/500 (Australia, New Zealand) | |
| Daivobet D.A.C. (Iceland) | |
| Daivobetoi (Oman) | |
| Dovobet Ointment (United Kingdom) | |
| Dyvon Plus (Bangladesh) | |
| Eccotriol (Egypt) | |
| Eczecort (Greece) | |
| Enstilar 50 μg/g + 0.5 mg/g (Austria) | |
| Enstilum (Belgium, Romania) | |
| Enstilum 50mcg/0.5mg (Luxembourg) | |
| Potribet (Bulgaria) | |
| Psorcutan Beta (Germany, Turkey) | |
| Psori-Bet (Argentina) | |
| Psoriasone (Tunisia) | |
| Token (Italy) | |
| Xamiol (Austria, Belgium, Bulgaria, Canada, Denmark, Estonia, Finland, France, Germany, Greece, Iceland, Italy, Latvia, Lithuania, Luxembourg, Malta, Norway, Oman, Philippines, Portugal, Slovenia, Sweden, Switzerland, Taiwan, Tunisia) | |
| Gel; Topical; Betamethasone Dipropionate 0.5 mg; Calcipotriol Monohydrate 50 mcg / g (LEO Pharma) | |
| Xamiol 30 g (LEO Pharma) | $ 41.98 |
| Xamiol 15 g x 1's (LEO Pharma) | |
| Xamiol 15 g (LEO Pharma) | |
| Xamiol topical gel 30 g x 1's (LEO Pharma) | $ 41.98 |
| Xamiol topical gel 15 g x 1's (LEO Pharma) | |
| Xamiol 50 Mikrogramm/g + 0,5 mg/g (Germany) | |
| Xamiol 50µg/0.5mg/g (Hungary, Luxembourg) | |
See 53 substitutes for Plaquverazon | |
References
- DailyMed. "CALCIPOTRIENE HYDRATE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- DailyMed. "BETAMETHASONE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- PubChem. "betamethasone". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Plaquverazon are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Plaquverazon. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yetConsumer reported time for results
No survey data has been collected yetConsumer reported age
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
